Phase 3 clinical trial has been given approval by FDA
The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).
Search
Search results
Johnson & Johnson gene therapy update – What happens now?
The latest research news from Retina UK.
Research grants
Retina UK aims not only to progress research along established threads, but to stimulate new thinking, encourage innovative approaches and nurture original ideas.
Meet a Researcher: Stéphanie Cornelis and Mubeen Khan
The project aims to develop a cost effective method of examining the entire ABCA4 gene to look for variations that might cause disease.
A blog from the research coal face
Jing Yu is a bioinformatician with the Eye Research Group at Oxford University, and is part of the UK Inherited Retinal Dystrophy Consortium (UKIRDC) team, funded by a Retina UK grant.
Drugs for cancer and alcoholism show promise for RP
With all the interest in exciting gene and cell therapies for inherited sight loss, it’s easy to forget that more traditional drugs can also hold promise.
Sepul Bio begins clinical trial of ultevursen for USH2A-associated RP
Sepul Bio begins clinical trial of ultevursen for USH2A-associated RP
Look Forward – Winter 2023 – Issue 181
Inside this edition, register now for our AI webinar on 7 December with Dr Nikolas Pontikos.
Autoimmune Retinopathy
Autoimmune diseases are quite distinct from inherited retinal dystrophies.
Thomas Pocklington Trust and Sight Loss Councils ‘Cut it back’ campaign
TPT and Sight Loss Councils: Cut it back campaign